Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer… | Phase 2 | withdrawn | May 10, 2017 | Mayo Clinic | lack of accrual | Enrollment / accrual |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell… | Phase 2 | withdrawn | Oct 27, 2017 | Military Institute od Medicine National Research Institute | Poor patient recruitment. | Enrollment / accrual |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated… | Phase 2 | terminated | Sep 27, 2011 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal… | N/A | terminated | Jan 3, 2014 | Duke University | The sponsor's clinical program for the agent used in this study was discontinued. | Other (stated, no rule matched) |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial… | Phase 2 | withdrawn | Feb 1, 2018 | University of California, San Francisco | Study withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | N/A | terminated | Dec 4, 2012 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Oct 10, 2012 | University of Washington | Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015. | Enrollment / accrual |
| NCT02530606 | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | N/A | withdrawn | Aug 21, 2015 | Stanford University | Efficacy | Efficacy / futility |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure… | Phase 2 | terminated | Jan 8, 2015 | UNC Lineberger Comprehensive Cancer Center | Data from first 12 subjects-primary endpoint not met. Data analysis underway. | Other (stated, no rule matched) |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or… | Phase 3 | withdrawn | Oct 3, 2018 | Hoffmann-La Roche | In the context of the ongoing evaluation of our data, we have determined that there is no need to… | Safety / toxicity |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination…(RENALVax-2) | Phase 2 | withdrawn | Jul 21, 2017 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled due to change in standard practice | Enrollment / accrual |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | Phase 2 | terminated | Aug 16, 2016 | Western Regional Medical Center | departure of PI from institution and poor population for study participation | Other (stated, no rule matched) |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases… | Early Phase 1 | terminated | Jul 5, 2017 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Phase 2 | terminated | Sep 25, 2015 | The University of Texas Health Science Center, Houston | Loss of laboratory performing molecular analysis | Other (stated, no rule matched) |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in… | Phase 2 | withdrawn | Jul 18, 2017 | National Cancer Institute (NCI) | The study was never approved by CTEP neither was it ever activated | Other (stated, no rule matched) |
| NCT01795365 | Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer | N/A | terminated | Feb 20, 2013 | Centre Hospitalier Universitaire Vaudois | Participants are no longer being examined and receiving intervention. | Other (stated, no rule matched) |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT02145390 | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant… | N/A | terminated | May 22, 2014 | University of Miami | Investigator Decision - Insufficient Accrual | Investigator |
| NCT01618838 | Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for… | N/A | terminated | Jun 13, 2012 | Georgetown University | The study only accrued 4 patients in 2 years, far below target (40). It was closed with no subject… | Enrollment / accrual |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic… | Phase 2 | terminated | Sep 10, 2007 | National Cancer Institute (NCI) | Closure was recommended by CTEP due to slow accrual. | Enrollment / accrual |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell… | Phase 1 | terminated | Mar 11, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02491411 | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With…(DEXTER) | N/A | terminated | Jul 8, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study is terminated due to lower enrollment | Enrollment / accrual |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer… | Phase 1 | terminated | Sep 9, 2010 | Wake Forest University Health Sciences | Study terminated due to funding issues | Funding |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Western Regional Medical Center | Investigator no longer at site to enroll patients or write up data | Investigator |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | Phase 2 | terminated | Dec 1, 2011 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02215161 | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory… | Phase 2 | terminated | Aug 13, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell… | Phase 2 | terminated | Dec 10, 2015 | vghtpe user | In most sites had difficult to recruitting subjects. | Enrollment / accrual |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation… | Phase 2 | withdrawn | May 11, 2017 | Medical University of South Carolina | This study is withdrawn due to feasibility issues. | Other (stated, no rule matched) |
| NCT02878980 | An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of… | N/A | withdrawn | Aug 25, 2016 | City of Hope Medical Center | Feasibility issues | Other (stated, no rule matched) |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of…(ADAPT) | Phase 3 | terminated | Apr 23, 2012 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously…(COMET-2) | Phase 3 | terminated | Jan 31, 2012 | Exelixis | Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307. | Other (stated, no rule matched) |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian… | — | terminated | May 12, 2009 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01275664 | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients… | N/A | terminated | Jan 12, 2011 | Gynecologic Oncology Group | Study terminated due to no patient population available | Other (stated, no rule matched) |
| NCT02412124 | Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With… | N/A | terminated | Apr 8, 2015 | City of Hope Medical Center | Feasibility issues | Other (stated, no rule matched) |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian… | Phase 1 | withdrawn | Jul 14, 2016 | Roswell Park Cancer Institute | production of adjuvant to be used with vaccine was discontinued by sponsor | Other (stated, no rule matched) |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02747173 | Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and…(METHEOS) | — | terminated | Apr 21, 2016 | Spanish Oncology Genito-Urinary Group | not stated | Not stated |
| NCT02441517 | A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer… | Phase 4 | terminated | May 12, 2015 | Astellas Pharma Global Development, Inc. | The study is closed early due to lck of enrollment. | Enrollment / accrual |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage… | Phase 2 | terminated | Jan 23, 2013 | The University of Texas Health Science Center at San Antonio | Lack of funding | Funding |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | Phase 1 | terminated | Mar 15, 2016 | Sanjiv Sam Gambhir | not stated | Not stated |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed… | Phase 1 / Phase 2 | terminated | Nov 4, 2010 | AEterna Zentaris | Poor recruitment | Enrollment / accrual |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | Phase 2 | terminated | Mar 7, 2018 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma… | Phase 2 | withdrawn | Nov 11, 2016 | University of Kansas Medical Center | Due to competing trials. Stopped before IRB approval. | Other (stated, no rule matched) |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal… | Phase 1 | terminated | Apr 10, 2014 | Fox Chase Cancer Center | IRB study closure by investigator due to low enrollment | Investigator |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and…(PGA) | Phase 2 | terminated | Sep 6, 2013 | Western Regional Medical Center | PI Decision | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 5, 2019source: clinicaltrials